Biocon subsidiary Biocon Biologics has successfully integrated Viatris‘ biosimilars business in 31 countries in Europe.
In November 2022, Biocon Biologics concluded the acquisition of Viatris’ international biosimilars business in a $3bn deal. The companies signed a definitive agreement for the acquisition in February 2023.
In July 2023, the company completed the related integration in more than 70 emerging market countries, going on to do so in North America in September.
The successful transition of the biosimilar operations of Viatris represents a major milestone in establishing Biocon as a leading global biosimilars company.
Biocon Biologics Commercial Europe & JANZ [Japan, Australia and New Zealand] head Jozef Belcik stated: “As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution, and commercialisation of biosimilars in Europe and the world.”
Biocon Biologics and its partners will sell biosimilar products to countries that include Albania, Bosnia, Hungary, Serbia, Switzerland and the UK.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Biocon Biologics CEO and managing director Shreehas Tambe stated: “The integration of the Viatris’ biosimilar business in Europe ahead of schedule is another important milestone for Biocon Biologics in our journey as a global biosimilars leader.
“We are pleased to expand access to life-saving treatments for patients across Europe. Our unique, fully integrated capabilities and a robust pipeline of 20 products will allow us to better address patient needs and be a reliable partner to health organisations.”
Biocon Biologics in Europe offers a portfolio comprising seven biosimilars: adalimumab, bevacizumab, etanercept, insulin aspart, insulin glargine, pegfilgrastim and trastuzumab.
The company has a lineup of 20 assets worldwide, focusing on bone health, diabetology, immunology, ophthalmology, and oncology.
